With 5-year survival rates remaining constant at 6% and rising incidences associated with an
epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is …

Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high mortality
rate. Genetic and biochemical studies have shown that RAS signaling mediated by KRAS …

Pancreatic cancer (PDAC) is one of the deadliest types of human cancers, owing to late stage
at presentation and pervasive therapeutic resistance. The extensive tumour heterogeneity, …

Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting
role is highly context dependent. Oncogenic Kras mutation is the signature event in …

Cancer cells have metabolic dependencies that distinguish them from their normal counterparts
1 . Among these dependencies is an increased use of the amino acid glutamine to fuel …

Macroautophagy (autophagy) is a regulated catabolic pathway to degrade cellular
organelles and macromolecules. The role of autophagy in cancer is complex and may differ …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western
countries, with a median survival of 6 months and an extremely low percentage of long-term …

Targeted therapies that inhibit receptor tyrosine kinases (RTKs) and the downstream
phosphatidylinositol 3-kinase (PI3K) signaling pathway have shown promising anticancer activity, …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by an
intense fibrotic stromal response and deregulated metabolism 1 , 2 , 3 , 4 . The role of the …

Glioblastoma (GBM) is a highly lethal brain tumour presenting as one of two subtypes with
distinct clinical histories and molecular profiles. The primary GBM subtype presents acutely as …